HanmiPharm is a South Korean pharmaceutical company that develops, manufactures, and sells prescription drugs, active pharmaceutical ingredients (APIs), and biopharmaceuticals. The company operates through three main business segments: pharmaceuticals, APIs, and overseas pharmaceuticals. In the pharmaceuticals segment, it markets improved and complex generic drugs such as Amozaltan for hypertension, Rosujet for dyslipidemia, Esomezol for gastroesophageal reflux disease, and Hanmitams for benign prostatic hyperplasia, while also focusing on the development of new drugs in areas including obesity, metabolic disorders, and oncology. The API segment, operated through its subsidiary Hanmi Precision Chemical, produces cephalosporin antibiotics and other raw materials for global pharmaceutical companies, and provides CDMO services for high-difficulty peptides, PEG, and mRNA raw materials. The overseas pharmaceuticals segment is managed by Beijing Hanmi Pharmaceutical, which sells products in China, including Mamai for pediatric gastrointestinal issues and Yitanjing for cough and phlegm. The company maintains R&D partnerships and has licensed out technologies to global partners, including Aptose Biosciences. HanmiPharm serves domestic and international markets, with a significant presence in South Korea and China, and exports APIs to numerous countries worldwide.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage hanmi.co.kr
Sector Healthcare IR page hanmi.co.kr/about/investor-relations/ir/event/list.hm
Tags
prescription drugs, active pharmaceutical ingredients, biopharmaceuticals, cdmo, obesity, metabolic disorders, oncology, antibiotics, peptides, mrna, Amozaltan, Rosujet, Esomezol, Hanmitams, Palfal, Mamai, Yitanjing, Meichang'an, Meiyaping, Hanmi Precision Chemical, Beijing Hanmi Pharmaceutical, Aptose Biosciences, BH3120, HM97662, Epe, Muzonalmac, Maxibufen, Tenten, Siliman
Press page hanmi.co.kr/about/news-media/press

Metrics

Valuation  
Market cap ₩ 6.46T
Market cap (USD) $ 4.754B
P/E 29.47
PEG 1.09
P/BV 4.60
P/S 3.90
P/OCF 23.67
P/FCF 29.86
Dividend yield —
Turnover / mcap —
Returns  
ROE 14.5%
ROI 13.6%
ROIC 18.1%
Profit margin 11.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 27.0%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 1.548T 1.496T 1.491T 1.332T 1.203T 1.076T 1.114T 1.016T 916.586B 882.725B 1.318T 761.28B 730.134B
Net profit 169.554B 121.315B 146.231B 82.792B 67.025B 11.959B 52.11B 24.891B 60.434B 23.326B 154.443B 35.51B 43.933B
Free cash flow 130.048B 154.226B 189.186B 132.949B 181.974B 109.719B -153.685B -156.286B -309.959B 212.708B -19.353B -101.999B 59.423B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 451.155K 275.325K — — — — — — — — — — —
Price performance 12m 0.64 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 272B 250B 183B 191B 150B 220B 180B 169B 239B 339B
↳ YoY growth -65.4% -7.8% -26.7% +4.1% -21.4% +46.6% -18.2% -6.1% +41.2% +42.0%
↳ 5y CAGR -3.7% -8.0% -28.2% -4.1% -6.4% -1.6% +4.6% +17.7%
Borrowings, current (KRW) 43.8B 278B 215B 297B 400B 400B 449B 481B 0.00 0.00
Borrowings, non-current (KRW) 49.7B 146B 217B 221B 179B 181B 142B 82B 85.9B 91.8B
Bonds payable (KRW) 50B 60B 0.00 50B 113B 100B 35B 75B 0.00 0.00
Cash and deposits (KRW) 130B 47.3B 67.3B 106B 146B 209B 147B 55B 192B 108B
Intangible assets (KRW) 40.1B 45.7B 60.7B 66.2B 72.9B 80.2B 84.6B 81B 94.1B 113B
Right-of-use assets (KRW) — 0.00 0.00 8.09B 13.4B 12.7B 30.4B 27B 26.9B 26.1B
Net debt (borrowings + leases - cash) (KRW) -36.9B 378B 365B 412B 433B 372B 445B 508B -106B -16.5B
Cash flow detail
Operating cash flow (KRW) 413B -62.9B 26B 12.4B 152B 202B 162B 217B 193B 173B
Purchases of property, plant and equipment (KRW) -200B -247B -182B -166B -41.8B -19.9B -29.3B -27.4B -39.3B -43B
Purchases of intangible assets (KRW) -23.8B -15.3B -29B -12.2B -16B -14.5B -20.3B -16.4B -23.3B -33.5B
Change in receivables (cash effect) (KRW) 527B -16.3B 58.6B -10.1B 32.5B 2.3B 904M 703M -61.1B -87.3B
Change in inventories (cash effect) (KRW) -34.7B -42.7B -27.1B -74.1B 4.88B 18.9B -14.4B -16.9B 1.93B -37B
Change in payables (cash effect) (KRW) -7.53B -3.3B 3.34B -7.14B -5.31B 9.79B -2.74B 5.57B -24.4B 256M
Dividends paid (cash effect) (KRW) -20.4B 0.00 -8.96B -5.66B -8.14B -5.88B -5.99B -18B -12.6B -30.9B
Share buybacks (cash effect) (KRW) -7.13B -6.45B -5.59B -3.87B -3.08B -4.87B -3.83B -3.07B -3.28B 0.00
Interest paid (cash effect) (KRW) -11.8B -13.3B -18.9B -23.3B -23.6B -18.3B -19.5B -27.8B -24.7B -17.1B
Income taxes paid (cash effect) (KRW) -11.8B -11B -13.7B -8.03B -14.7B -6.6B -29.6B -31.4B -22.1B -46.3B
Operating cash flow before change in receivables (KRW) -115B -46.6B -32.6B 22.5B 119B 200B 161B 216B 255B 260B
Free cash flow (OCF - PPE - intangibles) (KRW) 189B -325B -185B -166B 93.7B 167B 113B 173B 131B 96.5B
Income detail
Total comprehensive income (KRW) 17.3B 64.4B 27.9B 42.6B 20.7B 107B 94.8B 111B 175B 194B
Comprehensive income to owners (KRW) 12.1B 58.7B 19.2B 30.1B 15B 83.7B 78.8B 92.8B 142B 173B
Provision for credit losses (KRW) -2.25B 797M 2.15B 2.1B 374M 5.12B 723M 1.28B -594M 3.35B
Credit cost ratio (credit losses / average receivables) (%) 0.4% 0.3% 1.0% 1.1% 0.2% 2.8% 0.4% 0.7% 0.3% 1.2%
Reported Apr 2, 2018 Mar 30, 2020 Mar 30, 2020 Mar 30, 2020 Mar 18, 2021 Mar 19, 2024 Mar 19, 2024 Mar 19, 2024 Mar 18, 2025 Mar 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

기업설명회(IR)개최(안내공시) Bull 0 Bear 0 Routine
기업설명회(IR)개최(안내공시) Bull 0 Bear 0 Routine
기업설명회(IR)개최(안내공시) Bull 0 Bear 0 Routine

Prompts

HanmiPharm (ticker 128940), listed in South Korea.

ETFs Holding HanmiPharm

ETF Weight in ETF Shares Market value As of
OZEM 6.90% 11,503 $ 3.855M Nov 17, 2026
AVEE 0.23% 936 $ 307.273K Nov 16, 2026
DEHP 0.06% 638 $ 226.821K Nov 12, 2026
DEXC 0.04% 300 $ 106.656K Nov 12, 2026
DFSE 0.04% 623 $ 221.488K Nov 12, 2026
DFEM 0.03% 6,431 $ 2.286M Nov 12, 2026
DFAE 0.02% 4,619 $ 1.642M Nov 12, 2026
DFAX 0.01% 4,146 $ 1.474M Nov 12, 2026
AVEM 0.01% 5,573 $ 1.83M Nov 16, 2026
AVXC 0.01% 171 $ 56.136K Nov 16, 2026